Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhibition of DLX6 sensitizes lung adenocarcinoma to cisplatin via GPX4-dependent ferroptosis.

Cellular oncology (Dordrecht, Netherlands)·2026
Same author

Impact of chronic comorbidities on psychological and social status in COVID-19 patients.

Frontiers in psychology·2026
Same author

Resources and applications of public biomedical data.

Frontiers in bioinformatics·2026
Same author

Online Pairwise Comparisons Survey on Disability Weight for Chronic Cadmium Poisoning - Shenyang City, Liaoning Province, China, June-August 2022.

China CDC weekly·2026
Same author

A study on the antitumor effect and mechanism of arsenic trioxide on lung adenocarcinoma.

Journal of cancer research and therapeutics·2026
Same author

Multivariate genetic architecture of age-related eye disease.

PloS one·2026

Related Experiment Video

Updated: May 28, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Somatic Mutation Trajectories Define Prognostically Distinct Subtypes and Shape the Tumor Microenvironment in Gastric

Yikang Shen1, Huaxin Pang1, Haiyu Liu1

  • 1Data Center of Traditional Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.

Genes
|May 27, 2026
PubMed
Summary

Gastric cancer evolves along two distinct mutation paths, impacting survival and tumor microenvironment. Understanding these evolutionary trajectories can guide personalized treatment strategies.

Keywords:
computational genomicsgastric cancersomatic mutation trajectoriestumor evolutiontumor microenvironment

More Related Videos

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
07:50

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Published on: September 18, 2020

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Related Experiment Videos

Last Updated: May 28, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
07:50

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Published on: September 18, 2020

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Area of Science:

  • Oncology
  • Genomics
  • Computational Biology

Background:

  • Gastric cancer (GC) exhibits molecular heterogeneity, but current classifications overlook mutation accumulation order.
  • Understanding temporal mutation patterns is crucial for identifying prognostically distinct GC subtypes.

Purpose of the Study:

  • Reconstruct somatic mutation trajectories in GC using the SuStaIn algorithm.
  • Identify distinct GC subtypes based on mutation order.
  • Examine transcriptomic and microenvironmental features associated with these trajectories.

Main Methods:

  • Applied the Subtype and Stage Inference (SuStaIn) algorithm to TCGA-STAD somatic mutation data.
  • Performed stage-correlated gene expression analysis and tumor microenvironment (TME) characterization using EcoTyper and scRNA-seq deconvolution.
  • Evaluated clinical relevance in external cohorts and predicted drug sensitivity.

Main Results:

  • Identified two evolutionary trajectories: Accelerated Path (AP, 65%) and Gradual Path (GP, 35%).
  • AP shows earlier TP53 mutations, worse survival, SCN4A downregulation, and a stromal-enriched TME.
  • GP exhibits later TP53 mutations, SDHD-correlated expression, and higher inferred immune cell scores.

Conclusions:

  • Two distinct mutational ordering patterns in GC correlate with divergent transcriptomic features, TME, and clinical outcomes.
  • The AP subtype is linked to early TP53 mutations and a stromal-enriched microenvironment, while GP is associated with later TP53 mutations and higher immune cell scores.
  • Findings require prospective validation and offer hypothesis-generating insights for personalized GC therapy.